Navigation Links
Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma
Date:8/21/2007

jor programs that center on oligonucleotides (RNA- and DNA- based medicines) and small molecules. Genasense(R) (oblimersen sodium) Injection is the Company's lead compound from its oligonucleotide program. The leading drug in Genta's small molecule program is Ganite(R) (gallium nitrate injection), which the Company is exclusively marketing in the U.S. for treatment of symptomatic patients with cancer related hypercalcemia that is resistant to hydration. Genta is partnered with IDIS (http://www.idispharma.com) on a program whereby both Ganite(R) and Genasense(R) are available on a "named- patient" basis in countries outside the United States. For more information about Genta, please visit our website at: http://www.genta.com.

Safe Harbor

This press release may contain forward-looking statements with respect to business conducted by Genta Incorporated. By their nature, forward-looking statements and forecasts involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. Forward- looking statements include, without limitation, statements about:

* the Company's ability to obtain necessary regulatory approval for

Genasense(R) from the U.S. Food and Drug Administration ("FDA") or

European Medicines Agency ("EMEA");

* the safety and efficacy of the Company's products or product candidates;

* the Company's assessment of its clinical trials;

* the commencement and completion of clinical trials;

* the Company's ability to develop, manufacture, license and sell its

products or product candidates;

* the Company's ability to enter into and successfully execute license and

collaborative agreements, if any;

* the adequacy of the Company's capital resources and cash flow

projections, and the Company's ability to obtain sufficient
'/>"/>

SOURCE Genta Incorporated

Copyright©2007 PR Newswire.

Page: 1 2 3 4 5

Related medicine technology :

1. Genta Announces Results of Phase 1 Study Using Genasense Administered by Intermittent Subcutaneous Injection
2. Genta Incorporated to Present Multiple Abstracts at the Annual Meeting of the American Society of Clinical Oncology
3. Malvern initiates European user group meetings for chemical imaging
4. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
5. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
6. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... 23, 2015 More than a third of reproductive-aged women ... with private insurance, filled a prescription for an opioid pain ... this week,s Morbidity and Mortality Weekly Report (MMWR). ... treat moderate to severe pain.  They are also found in ...
(Date:1/23/2015)... , Jan. 23, 2015 /PRNewswire/-- Harwood Feffer LLP ( ... of directors of Advaxis, Inc. ("Advaxis" or the "Company") ... has breached its fiduciary duties to shareholders. ... an investing website reporting that Advaxis had misrepresented the ...
(Date:1/23/2015)... Fla. , Jan. 23, 2015  HyGreen, Inc., a ... agreement and partnership with RCA Medical, a subsidiary of ... . Each year, hundreds of millions ... care-associated infections as organisms are transmitted from patient to ...
Breaking Medicine Technology:Opioid painkillers widely prescribed among reproductive age women 2Opioid painkillers widely prescribed among reproductive age women 3Harwood Feffer LLP Announces Investigation of Advaxis, Inc. 2HyGreen Partners with RCA Medical in Johannesburg, South Africa 2
... Roche announced today that three,clinical data abstracts about its ... the 2007 Breast Cancer Symposium in San,Francisco, Sept. 7 ... from the XeNA (Xeloda in NeoAdjuvant),trial, a study of ... invasive breast cancer. The third presentation highlights,findings that validate ...
... 6 454 Life Sciences, a Roche,company, today announced ... identified a virus implicated in the deaths of,2.4 million ... using the,company,s Genome Sequencer(TM) system. The findings explain ... identified by reading sequences of DNA isolated from the ...
Cached Medicine Technology:Xeloda XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium 2Xeloda XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium 3Researchers Identify Virus Possibly Responsible for Declining Honeybee Population Using 454 Sequencing Technology from Roche 2Researchers Identify Virus Possibly Responsible for Declining Honeybee Population Using 454 Sequencing Technology from Roche 3Researchers Identify Virus Possibly Responsible for Declining Honeybee Population Using 454 Sequencing Technology from Roche 4
(Date:1/22/2015)... York (PRWEB) January 22, 2015 The federal ... in the U.S. District Court, Southern District of West Virginia ... Inc. in that proceeding’s first bellwether trial. In an Order ... a new trial after finding that C.R. Bard had not ...
(Date:1/22/2015)... has released a new blog post explaining the main features ... , Auto insurance quotes help many drivers find the best ... call an agent or visit an agency for price information. ... http://autocarinsurancebest.com/ . , Every business who relies heavily on ...
(Date:1/22/2015)... NY (PRWEB) January 22, 2015 ... of Sports Medicine flagship journal Medicine & Science ... L-Citrulline before exercise may help reduce gastrointestinal (GI) ... 1 , Participants in the double-blind, placebo-controlled ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Four years since the ... – which coincided with the marriage of Avasa & Matthew Love ... ROAD, which is scheduled for release through White Swan Records on ... that there is a sacred path available to all of us ...
(Date:1/22/2015)... JJsHouse.com is a famous dress online store ... announces its latest collection of wedding dresses , and ... issue is the wedding dress on your big day; the ... life. Every bride wants to find the most suitable wedding ...
Breaking Medicine News(10 mins):Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:Commercial Auto Insurance Provides Several Important Features! 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 2Health News:THE ROAD by Avasa & Matthew Love -- A New Album 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 4Health News:Find The Most Suitable Wedding Dress At JJsHouse.com 2
... Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUN ... Company Exclusive Group Ltd. (Alkaloida), has extended the Expiration ... all outstanding Ordinary Shares of Taro Pharmaceutical Industries Ltd. ... p.m., New York City time, on Friday, April 3, ...
... cognitive disorders, researchers say , , FRIDAY, March 20 ... "the edge of chaos," at a critical point ... who said their finding could help improve understanding ... The researchers used medical imaging to measure changes ...
... some groups, survival odds after angioplasty are not as ... major international study pinpoints which people with major heart ... than artery-opening angioplasty. , "Bypass surgery is preferable for ... Hlatky, professor of health research and policy and cardiovascular ...
... - Mayo Clinic research shows a correlation between inadequate ... taken by patients who have chronic pain. This correlation ... to treat chronic pain. According to the Centers for ... cause of disability in the United States. These patients ...
... Lead to a New Definition of ,Bedside Manner,WASHINGTON and ... Health Resource Center (NWHRC) just released the latest issue ... "Women & Health Care Reform." The report coincides ... effort to gain support and awareness of the need ...
... N.C., March 20 The Government of Kenya ... 870 health workers contracted over the past three ... the country,s severe shortage of health professionals.Designed to ... public health facilities using a private-sector outsourcing mechanism, ...
Cached Medicine News:Health News:Sun Pharmaceutical Extends Tender Offer for Taro 2Health News:Sun Pharmaceutical Extends Tender Offer for Taro 3Health News:Diabetics and Elderly May Fare Better With Bypass 2Health News:Diabetics and Elderly May Fare Better With Bypass 3Health News:Mayo Clinic Study Suggests Those Who Have Chronic Pain May Need to Assess Vitamin D Status 2Health News:Mayo Clinic Study Suggests Those Who Have Chronic Pain May Need to Assess Vitamin D Status 3Health News:National Women's Health Report Addresses Issues of Uninsured Plus New Paradigms of Care 2Health News:Kenya Government Appoints Emergency Health Workers to Permanent Positions 2Health News:Kenya Government Appoints Emergency Health Workers to Permanent Positions 3
... Freedom leg bags are part ... a versatile line of leg bags, ... the varied needs of our customers. ... several sizes, and constructed of 100% ...
... are part of the Freedom Urinary ... leg bags, kits, and accessories designed ... our customers. These leg bags are ... of 100% latex-free soft, textured medical ...
... line of Personal Catheters® ... you would choose for ... configurations - standard, antibacterial, ... - are based on ...
The Antibacterial Personal Catheter® features a unique silicone composition that provides an antibacterial coated soft outer layer of silicone combined with a firm inner layer....
Medicine Products: